EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival

Rongzhi Wang iD, Rhiannon D Reed, Griffin Price, Peter Abraham, Marshall Lewis, Jessica Liu McMullin, Paul MacLennan, Cozette Killian, Jayme E Locke, Song Ong, Vineeta Kumar, Andrea Gillis iD und 3 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Rongzhi Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Hypercalcemia, Kidney Transplantation, Hyperparathyroidism, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperparathyroidism (HPT) and malignancy are the most common causes of hypercalcemia. Among kidney transplant (KT) recipients, hypercalcemia is mostly caused by tertiary HPT. Persistent tertiary HPT after KT is associated with allograft failure. Previous studies on managing tHPT were subjected to survivor treatment selection bias; as such, the impact of tertiary HPT treatment on allograft function remained unclear. We aim to assess the association between hypercalcemic tertiary HPT treatment and kidney allograft survival. Materials and Methods We identified 280 KT recipients (2015-2019) with elevated post-KT adjusted serum calcium and parathyroid hormone (PTH). KT recipients were characterized by treatment: cinacalcet, parathyroidectomy, or no treatment. Time-varying Cox regression with delayed entry at the time of first elevated post-KT calcium was conducted, and death-censored and all-cause allograft failure were compared by treatment groups.

Results

Of the 280 recipients with tHPT, 49 underwent PTx, and 98 received cinacalcet. The median time from KT to first elevated calcium was 1 month (IQR: 0-4). The median time from first elevated calcium to receiving cinacalcet and parathyroidectomy was 0(IQR: 0-3) and 13(IQR: 8-23) months, respectively. KT recipients with no treatment had shorter dialysis vintage (P = .017) and lower PTH at KT (P = .002), later onset of hypercalcemia post-KT (P < .001). Treatment with PTx (adjusted hazard ratio (aHR) = 0.18, 95%CI 0.04-0.76, P = .02) or cinacalcet (aHR = 0.14, 95%CI 0.004-0.47, P = .002) was associated with lower risk of death-censored allograft failure. Moreover, receipt of PTx (aHR = 0.28, 95%CI 0.12-0.66, P < .001) or cinacalcet (aHR = 0.38, 95%CI 0.22-0.66, P < .001) was associated with lower risk of all-cause allograft failure.

Conclusions

This study demonstrates that treatment of hypercalcemic tertiary HPT post-KT is associated with improved allograft survival. Although these findings are not specific to hypercalcemia of malignancy, they do demonstrate the negative impact of hypercalcemic tertiary HPT on kidney function. Hypercalcemic HPT should be screened and aggressively treated post-KT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaKidney TransplantationHyperparathyroidismNeoplasmsHyperparathyroidism, SecondaryHumansCinacalcetCalciumParathyroid HormoneParathyroidectomyAllograftsRetrospective Studies

Stichwörter der Autor:innen

allograft functionhypercalcemiahyperparathyroidismkidney transplant

Substanzen

CinacalcetCalciumParathyroid Hormone

Autor:innen und Institutionen

  • Department of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • School of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • Department of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

ORCID-Profile: Rongzhi Wang, Andrea Gillis

Zitieren

APA

Wang, R., Reed, R. D., Price, G., Abraham, P., Lewis, M., McMullin, J. L., MacLennan, P., Killian, C., Locke, J. E., Ong, S., Kumar, V., Gillis, A., Lindeman, B., Chen, H., & Fazendin, J. (2024). Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival. The Oncologist. https://doi.org/10.1093/oncolo/oyad314

Vancouver

Wang R, Reed RD, Price G, Abraham P, Lewis M, McMullin JL, et al. Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival. The Oncologist. 2024. doi:10.1093/oncolo/oyad314

BibTeX
@article{Wang2024,
  author = {Wang, Rongzhi and Reed, Rhiannon D and Price, Griffin and Abraham, Peter and Lewis, Marshall and McMullin, Jessica Liu and MacLennan, Paul and Killian, Cozette and Locke, Jayme E and Ong, Song and Kumar, Vineeta and Gillis, Andrea and Lindeman, Brenessa and Chen, Herbert and Fazendin, Jessica},
  title = {Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad314}
}
Kostenlos starten →